Nathaniel Ashford

Mr. Nathaniel Ashford


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2025 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
IBIan H. de Boer
Ian H. de Boer
LALisa D. Anderson
Lisa D. Anderson
NANathaniel Ashford
Nathaniel Ashford
EAErnest Ayers
Ernest Ayers
NBNisha Bansal
Nisha Bansal
LZLeila R. Zelnick
Leila R. Zelnick
Key Points: In maintenance dialysis, continuous glucose monitoring frequently identified both hyperglycemia and hypoglycemia that may not be clinically evident. Patients with treated diabetes rarely met contemporary continuous glucose monitoring–based treatment targets. Background: Kidney failure and its treatments disrupt glucose homeostasis in ways that may promote both hyperglycemia and hypoglycemia. Continuous glucose monitoring (CGM) delineates detailed glycemic profiles, but published studies in kidney failure are limited to small, select groups. We aimed to characterize the spectrum of glycemia and its determinants in a large, diverse maintenance dialysis population. Methods: We conducted a prospective community-based cohort study of people treated with maintenance dialysis. Each participant wore a Dexcom G6 Pro CGM for approximately 10 days. Outcomes ascertained by CGM included mean blood glucose, time in range (TIR, 70–180 mg/dl), and hypoglycemia events (sustained <70 mg/dl). Results: We enrolled 420 demographically diverse participants, including 263 with diabetes (of whom 88 were untreated with glucose-lowering medications) and 157 without diabetes. Peritoneal dialysis (PD) was used by 55 participants. Outcomes varied by diabetes status and dialysis modality. Among participants without diabetes, mean blood glucose was higher with PD versus hemodialysis (141 versus 121 mg/dl, P < 0.001). Among participants with untreated diabetes, the mean blood glucose was 162 mg/dl, mean TIR 71%, and only 64% of participants attained TIR ≥70%, while mean hemoglobin A1c (HbA1c) was 5.7%. Among participants with treated diabetes, the mean blood glucose was 214 mg/dl, the mean TIR was 43%, and only 22% of participants attained TIR ≥70%, while the mean HbA1c was 7.0%. In total, 714 unique sustained hypoglycemia events were observed, with highest rates for participants without diabetes. In addition to diabetes and dialysis modality, age, dialysis vintage, insulin use, HbA1c, and serum albumin were significantly associated with mean blood glucose, hypoglycemia, or both. Conclusions: In maintenance dialysis, CGM frequently identified both hyperglycemia and hypoglycemia that may not be clinically evident. In particular, hyperglycemia was common with PD, patients with untreated diabetes maintained a diabetic glycemic profile, and patients with treated diabetes rarely met contemporary CGM-based treatment targets.

6 November 2024 in European Burn Journal
Verified
Journal Article
Open access
SSStephen Sibbett
Stephen Sibbett
JOJamie Oh
Jamie Oh
Gretchen J. CarrougherGretchen J. Carrougher
Gretchen J. Carrougher
LMLara Muffley
Lara Muffley
NANathaniel Ashford
Nathaniel Ashford
Nicole S. GibranNicole S. Gibran
Nicole S. Gibran
In this study, we aimed to integrate a genetic repository with an existing longitudinal national burn database. We set out two primary objectives, namely (1) to develop standard operating procedures for genetic sample collection and storage, DNA isolation, and data integration into an existing multicenter database; and (2) to demonstrate the feasibility of correlating genetic variation to functional outcomes in a pilot study, using the catechol-O-methyltransferase (COMT) gene. Dubbed the worrier/warrior gene, COMT variants have been associated with varying phenotypes of post-traumatic stress, wellbeing, and resilience. Between August 2018 and July 2020, COMT variants were identified for 111 participants from three sites and correlated with their outcome data. We found no association between COMT variants and functional outcomes, likely due to the inadequate sample size. We also asked all potential participants why they consented to or refused genetic analysis. A thematic analysis of responses revealed altruism and personal interest/enthusiasm in the study as top reasons for consenting. Privacy concerns were the most common reason for refusal. In conclusion, we successfully developed standard operating procedures for genetic sample collection and storage, DNA isolation, and data integration into an existing database, and we demonstrated the feasibility of conducting a multicenter collaborative study using a centralized lab location.

3 April 2025 in Kidney360
Verified
Journal Article
Open access
BLBenjamin Lidgard
Benjamin Lidgard
NBNisha Bansal
Nisha Bansal
NANathaniel Ashford
Nathaniel Ashford
LZLeila R. Zelnick
Leila R. Zelnick
IBIan H. de Boer
Ian H. de Boer
Key Points: Heart rate variability (HRV) metrics did not significantly change over the course of hemodialysis sessions, suggesting poor autonomic function during dialysis. A novel device (Elite HRV CorSense) accurately measured time-domain (but not frequency-domain) HRV metrics compared with a gold-standard electrocardiogram device. Background: Decreased heart rate variability (HRV) is a measure of poor cardiovascular health and inability of the autonomic nervous system to respond to stress. Accumulation of uremic toxins in kidney failure, volume shifts, and clearance of uremic toxins by dialysis may affect HRV. We sought to evaluate how HRV changes over the course of hemodialysis sessions and evaluate a novel HRV sensor. Methods: Among 22 participants treated with in-center hemodialysis, we evaluated time-domain and frequency-domain HRV metrics with a gold-standard electrocardiogram (ECG) device (Schiller Cardiovit AT-10 Plus) and a novel fingertip sensor (Elite HRV CorSense) at five time points during two consecutive dialysis sessions. Changes over the session were evaluated by linear mixed models with random effect terms for participant and session. Devices were compared using correlation coefficients, Wilcoxon rank-sum tests, and linear regression. Results: There were no significant changes in HRV metrics over the dialysis session (P value for trend across ECG 0.11, across CorSense 0.58). Time-domain HRV metrics were moderately correlated between the two methods (correlation coefficient for SD of N-N interval 0.72 and for RMSSD 0.66), whereas frequency-domain methods were not. Linear models comparing CorSense and ECG readings suggested strong association for time-domain metrics. Conclusions: HRV metrics did not significantly change over the course of hemodialysis sessions, suggesting poor autonomic function during dialysis. A novel fingertip sensor accurately measured time-domain (but not frequency-domain) HRV metrics when compared with a gold-standard ECG device.

31 December 2021 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
PDF file
NANathaniel Ashford
Nathaniel Ashford
SRSwati Rane
Swati Rane
TGTarun Gandhi
Tarun Gandhi
KFKristen Farris
Kristen Farris
AHAngela J. Hanson
Angela J. Hanson

19 May 2025 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
NANathaniel Ashford
Nathaniel Ashford
SRSwati Rane
Swati Rane
KFKristen M Farris
Kristen M Farris
JMJasroop Miglani
Jasroop Miglani
BCBaocheng Chu
Baocheng Chu
AHAngela J Hanson
Angela J Hanson
Background: Hypertension and the APOE4 allele are known risk factors for Alzheimer's disease (AD) and E4 carriers show different blood pressure (BP) and cognitive responses to high fat feeding. Objective: We investigated the influence of these factors on global cerebral blood flow (CBF) and four regions of interest (ROIs) (angular gyrus, hippocampus, posterior cingulate, temporal lobe) using arterial spin labeling (ASL) MRI in fasting state and after ingestion of heavy cream in older adults. Methods: 29 adults (age in years 66.8 ± 4.1) underwent baseline and 1, 2, 3-h ASL MRI after ingestion of 100 mL heavy cream. We used pCASL MRI with background suppression to measure CBF in ml/100 g/min. Statistical analyses included mixed-effects modeling and Pearson correlation to ascertain whether CBF changed over time and how variables influenced results. Results: Global CBF decreased at 1-, 2-, and 3-h post-heavy cream, compared to time 0 (overall change 7.11%, p < 0.01); recapitulated in 3 of 4 ROIs. Mean arterial pressure emerged as a predictive variable for both baseline and post-heavy cream CBF (β = −0.25, 95% CI = −0.39, −0.10, p = 0.002). Individuals with higher BP demonstrated reduced CBF, particularly in posterior cingulate and temporal lobe (β = −5.50, 95% CI = −9.9, −1.09; β = −6.28, 95% CI = −12.35, −0.21, respectively, both p < 0.05). Examination of correlations with BP and change scores revealed that this relationship was driven largely by E4 carriers. Conclusions: CBF decreased after ingestion of heavy cream, globally and in regions known to be important in AD, and this finding was driven by E4 carriers with higher BP.